1 / 11

Benefit and Managing the Risk

Benefit and Managing the Risk. Dr. Neville Jackson. Benefit. As efficacious as short-acting SC regular insulin in patients with type 1 diabetes or insulin requiring type 2 diabetes Effective in type 2 DM used alone, in combination with basal insulin, and in combination with oral agent

kerem
Télécharger la présentation

Benefit and Managing the Risk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Benefit and Managing the Risk Dr. Neville Jackson

  2. Benefit • As efficacious as short-acting SC regular insulin in patients with type 1 diabetes or insulin requiring type 2 diabetes • Effective in type 2 DM used alone, in combination with basal insulin, and in combination with oral agent • Provides long-term glycemic control in both type 1 and type 2 diabetes • Most patients preferred INH over previous SC insulin and OA treatments

  3. Risks • Hypoglycemia event rates as for other insulins • Increased insulin antibodies compared to injected insulins • No association with clinical outcomes • Pulmonary effects • Cough – mostly post-inhalational • PFT declines – small, early, non-progressive, reversible • Risk management plan to explore mechanism and follow the longer-term effect

  4. Risk Minimization and Proposed Studies

  5. Education and Customer Care • Labeling • Call center • Healthcare professional training • Patient training support • Instruction video • Instruction manual • Quick reference guide • Device replacement • Enhanced pharmacovigilance to increase the follow up on the reporting of rare respiratory adverse events

  6. Use of 1 mg and 3 mg Blisters in the Clinical Program • 1 mg and 3 mg blisters were used safely and effectively in the clinical program • All patients were dispensed 1 mg and 3 mg blisters at treatment initiation • Patients were instructed to self-titrate by 1 mg increments, dependent upon home glucose monitoring • Instructions were given to use as few blisters as possible at each dosing session

  7. Pre-Breakfast Pre-Lunch Pre-Supper Use of Doses in Phase 3 Efficacy Studies Percent of Patients Dose (mg insulin, nominal)

  8. Proposed Dosing Information for the Label

  9. Assuring Safe Use of 1 & 3 mg Blisters • Education of patients to self-titrate by 1 mg increments • Clear tactile and visual differentiation of the blisters • Education of physicians to closely monitor patients on initiation of INH therapy • Manage the risk of substitution of 1 x 3 mg with 3 x 1 mg blisters by clear labeling, including secondary packaging, and education • Where unavoidable substitution is necessary, specific instructions to use 2 x 1 mg in place of 1 x 3 mg

  10. Risk Management - Protocols

  11. Multinational, Long-term Large Simple Trial to Evaluate Pulmonary Safety • Objectives • Persistent decline in FEV1 of 20% or more • Serious respiratory adverse events • Enroll 5,000 patients - North America, Europe, LA • Broad entry criteria as per approved label • Recruitment from primary care practices with diverse patient population • Targeted recruitment of 5-10% very elderly (75 years) • Randomization to Exubera or usual care for 5 years • Spirometry measurements (FEV1) at baseline and then prospectively, consistent with approved label • Follow up per usual medical care with concomitant medications permitted • All randomized patients followed for collection of SAEs even if they discontinue treatment

More Related